<SEC-DOCUMENT>0001628280-24-003693.txt : 20240207
<SEC-HEADER>0001628280-24-003693.hdr.sgml : 20240207
<ACCEPTANCE-DATETIME>20240207160708
ACCESSION NUMBER:		0001628280-24-003693
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240207
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240207
DATE AS OF CHANGE:		20240207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vanda Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001347178
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				030491827
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34186
		FILM NUMBER:		24604329

	BUSINESS ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
		BUSINESS PHONE:		202-734-3400

	MAIL ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vnda-20240207.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vnda-20240207</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001347178</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vnda-20240207.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-07</xbrli:startDate><xbrli:endDate>2024-02-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i527c0116fc6e443283d47c9e83b3723c_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February&#160;7, 2024</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">VANDA PHARMACEUTICALS INC.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:34.212%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.214%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-34186</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">03-0491827</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File No.)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2200 Pennsylvania Avenue NW</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 300E</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Washington</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">DC</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">20037</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">202</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">734-3400</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Former Name or Former Address, if Changed Since Last Report)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.292%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"/><td style="width:2.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.942%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.815%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.943%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">VNDA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-bottom:1pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i527c0116fc6e443283d47c9e83b3723c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.02.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations and Financial Condition.</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;7, 2024, Vanda Pharmaceuticals Inc. (&#8220;Vanda&#8221;) issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter and full year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various statements to be made during the conference call are &#8220;forward-looking statements&#8221; under the securities laws, including, but not limited to, statements regarding Vanda&#8217;s commercial products, plans and opportunities, as well as statements about Vanda&#8217;s products in development and the related clinical development and regulatory timelines and commercial potential for such products. Words such as, but not limited to, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and &#8220;could,&#8221; or the negative of these terms and similar expressions or words, identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important factors that could cause actual results to differ materially from those reflected in Vanda&#8217;s forward-looking statements include, among others, Vanda&#8217;s assumptions regarding the strength of its business in the U.S. and Vanda&#8217;s ability to complete the clinical development of, and obtain regulatory approval for, the products in its pipeline. Therefore, no assurance can be given that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements made during the call should be evaluated together with the various risks and uncertainties that affect Vanda&#8217;s business and market, particularly those identified in the &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;, &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of Vanda&#8217;s most recent Annual Report on Form 10-K, as updated by Vanda&#8217;s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. The information contained in this Current Report on Form 8-K is intended to be considered in the context of Vanda&#8217;s filings with the SEC and other public announcements that Vanda makes, by press release or otherwise, from time to time. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information conveyed on the conference call will be provided only as of the date of the call, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements made during the call after the date thereof, whether as a result of new information, future events or otherwise, except as required by law.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.637%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.01.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Exhibits</span></div><div style="text-indent:9pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.918%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vnda8-k272024exhibit991.htm">Press release of Vanda Pharmaceuticals Inc. dated February 7, 2024.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i527c0116fc6e443283d47c9e83b3723c_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:5.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 7, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VANDA PHARMACEUTICALS INC.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy Williams</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy Williams</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, General Counsel and Secretary</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vnda8-k272024exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2067d6f0c0ae44069ff03d1c80555484_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><img alt="vandaq32019earningsca_imag.jpg" src="vandaq32019earningsca_imag.jpg" style="height:88px;margin-bottom:5pt;vertical-align:text-bottom;width:264px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;margin-top:18pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Full year 2023 revenues were $192.6 million</font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> acquisition completed in Q4 2023 and transition ongoing</font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">3 FDA PDUFA target action dates in 2024</font></div><div style="margin-bottom:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Ended 2023 with approximately $388 million in cash and cash equivalents</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; February&#160;7, 2024 &#8211; Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq&#58; VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2023.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Despite significant external commercial and regulatory challenges, last year was a landmark year for Vanda, as we supported our commercial programs and, through a transformational deal, we added PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our portfolio alongside Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; said Mihael H. Polymeropoulos, M.D., Vanda&#8217;s President, CEO and Chairman of the Board. &#8220;At the same time, we advanced our clinical development pipeline with three NDA and sNDA submissions for insomnia, bipolar disorder and gastroparesis. Looking forward to this year, we are committed to advancing our clinical development pipeline and strengthening our commercial presence with a portfolio of innovative products serving unmet patient needs.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Highlights</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fourth Quarter of 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total net product sales from HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $45.3 million in the fourth quarter of 2023, a 30% decrease compared to $64.5 million in the fourth quarter of 2022, and a 17% increase compared to $38.8 million in the third quarter of 2023.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $21.1 million in the fourth quarter of 2023, a 47% decrease compared to $40.1 million in the fourth quarter of 2022, and a 20% increase compared to $17.5 million in the third quarter of 2023. The decrease relative to the fourth quarter of 2022 was the result of the at-risk launch of generic versions of HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $22.6 million in the fourth quarter of 2023, a 7% decrease compared to $24.4 million in the fourth quarter of 2022, and a 6% increase compared to $21.3 million in the third quarter of 2023.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $1.6 million in the fourth quarter of 2023. These net product sales reflect the revenue generated during the period between the product acquisition date of December 7, 2023 and December 31, 2023.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss was $2.4 million in the fourth quarter of 2023 compared to net income of $6.9 million in the fourth quarter of 2022, and net income of $0.1 million in the third quarter of 2023.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash, cash equivalents and marketable securities (Cash) was $388.3 million as of December 31, 2023, representing a decrease to Cash of $101.6 million compared to September 30, 2023. During the period, Vanda completed the acquisition of PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson &#38; Johnson Company, for $100.0 million.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Full Year 2023</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total net product sales from HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $192.6 million for the full year 2023, a 24% decrease compared to $254.4 million for the full year 2022.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $100.2 million for the full year 2023, a 37% decrease compared to $159.7 million for the full year 2022. The decrease was the result of the at-risk launch of generic versions of HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $90.9 million for the full year 2023, a 4% decrease compared to $94.7 million for the full year 2022.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net product sales were $1.6 million for the full year 2023. These net product sales reflect the revenue generated during the period between the product acquisition date of December 7, 2023 and December 31, 2023.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net income was $2.5 million for the full year 2023 compared to net income of $6.3 million for the full year 2022.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash, cash equivalents and marketable securities (Cash) was $388.3 million as of December 31, 2023, representing a decrease to Cash of $78.6 million, or 17%, compared to December 31, 2022. During the period, Vanda completed the acquisition of PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Janssen for $100.0 million.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Operational Highlights </font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> (tasimelteon)</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The supplemental New Drug Application (sNDA) for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of insomnia is under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of March 4, 2024. Vanda announced that on February 4, 2024, it received a notification from the FDA stating that the FDA had identified deficiencies that preclude discussion of labeling and postmarketing requirements&#47;commitments at this time. No deficiencies were disclosed by the FDA in the notification, and the FDA stated that the notification does not reflect a final decision on the information under review. On February 6, 2024, Vanda filed suit in the U.S. District Court for the District of Columbia (D.C. District Court) challenging the FDA&#8217;s conduct in reviewing the insomnia sNDA. Vanda is asking the D.C. District Court to compel the FDA to adhere to the legally mandated 180-day review period for sNDAs and to declare as unlawful and void the regulations the FDA relies upon to issue complete response letters.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda is also continuing to pursue FDA approval for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of jet lag disorder. Vanda announced in January 2024 that the D.C. District Court granted Vanda&#8217;s motion for summary judgment on its claim against the FDA for unlawfully delaying a hearing on the approvability of Vanda&#8217;s sNDA for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of jet lag disorder. The D.C. District Court ordered the FDA to either finally resolve Vanda&#8217;s jet lag sNDA or commence a hearing on the sNDA on or before March 5, 2024.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2024, Vanda filed a petition for a writ of certiorari with the U.S. Supreme Court to review the decision of the U.S. Court of Appeals for the Federal Circuit in Vanda&#8217;s HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Abbreviated New Drug Application (ANDA) litigation against Teva Pharmaceuticals USA, Inc. (Teva), Apotex Inc. and Apotex Corp. (collectively, Apotex). Teva and Apotex have waived their opportunity to respond to Vanda&#8217;s petition, which is now ripe for decision by the U.S. Supreme Court.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> (iloperidone)</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The article &#8220;Efficacy and Safety of Iloperidone in Bipolar Mania&#58; A Double-Blind, Placebo-Controlled Study&#8221; was published in January 2024 in the Journal of Clinical Psychiatry.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The findings of this pivotal study have been submitted to the FDA as part of Vanda's sNDA for Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of bipolar I disorder in adults.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The sNDA for Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of bipolar I disorder in adults is under review by the FDA with a PDUFA target action date of April 2, 2024.</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> (ponesimod)</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda completed the acquisition of the U.S. and Canadian rights to PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Janssen for $100.0 million in December 2023 and the transition is ongoing. PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a once-daily oral selective sphingosine-1-phosphate receptor 1 modulator, approved by the FDA and Health Canada to treat adults with relapsing forms of multiple sclerosis, and is a potential therapeutic candidate for the treatment of a diverse group of inflammatory&#47;autoimmune disorders ranging from psoriasis to ulcerative colitis.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda announced in January 2024 that the U.S. Patent and Trademark Office (USPTO) had issued a notice of allowance for its PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent application, 17&#47;962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinstating treatment after missed doses. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When issued, the patent is anticipated to expire on October 10, 2042. Upon issuance, Vanda intends to list this patent in the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Tradipitant</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The article &#8220;The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial&#8221; was published in January 2024 in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Gastroenterology and Hepatology Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The findings of this pivotal study as well as a previously reported positive placebo-controlled study in diabetic and idiopathic gastroparesis have been submitted to the FDA as part of Vanda&#8217;s New Drug Application (NDA) for tradipitant in the treatment of symptoms of gastroparesis in adults.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2023, Vanda announced that the NDA for tradipitant for the treatment of symptoms of gastroparesis was accepted for filing and is under review by the FDA with a PDUFA target action date of September 18, 2024.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The second Phase III study of tradipitant in the treatment of motion sickness is over 50% enrolled. In May 2023, Vanda previously announced positive results from its first Phase III study of tradipitant in the treatment of motion sickness. Vanda plans to pursue FDA approval upon completion of the clinical development program.</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Early-Stage Programs</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2024, Vanda announced that the FDA had approved the Investigational New Drug (IND) application to evaluate VCA-894A for the treatment of a patient with Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), an inherited peripheral neuropathy for which there is no available treatment.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2024, Vanda announced that the FDA had also approved the IND to evaluate VTR-297 for the treatment of onychomycosis, a fungal infection of the nail.</font></div><div style="margin-top:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Legal Updates</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vanda announced in January 2024 that the United States Court of Federal Claims denied in part the U.S. government&#8217;s motion to dismiss Vanda&#8217;s claims against the U.S. for the FDA&#8217;s uncompensated taking of Vanda's trade secrets and confidential information, thereby allowing Vanda&#8217;s lawsuit to proceed. Vanda is seeking compensation from the U.S. for the takings it contends occurred through the FDA's improper communication and disclosure of trade secrets and confidential information to certain generic drug manufacturers. Vanda now intends to engage in discovery to support its claims.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GAAP Financial Results</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $2.4 million in the fourth quarter of 2023 compared to net income of $6.9 million in the fourth quarter of 2022. Diluted net loss per share was $0.04 in the fourth quarter of 2023 compared to diluted net income per share of $0.12 in the fourth quarter of 2022.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income was $2.5 million for the full year 2023 compared to net income of $6.3 million for the full year 2022. Diluted net income per share was $0.04 for the full year 2023 compared to diluted net income per share of $0.11 for the full year 2022.</font></div><div style="margin-bottom:6pt;margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024 Financial Guidance </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given uncertainties surrounding the U.S. market for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Non-24 as a result of the ongoing HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent litigation and the at-risk launch of generic versions of HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vanda is unable to provide 2024 financial guidance at this time. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda has scheduled a conference call for today, Wednesday, February&#160;7, 2024, at 4&#58;30 PM ET. During the call, Vanda&#8217;s management will discuss the fourth quarter and full year 2023 financial results and other corporate activities. Investors can call 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode number 8053170. A replay of the call will be available on Wednesday, February&#160;7, 2024, beginning at 8&#58;30 PM ET and will be accessible until Wednesday, February&#160;14, 2024 at 11&#58;59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 8053170.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conference call will be broadcast simultaneously on Vanda&#8217;s website, www.vandapharma.com. Investors should click on the Investors tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda&#8217;s website for a period of 30 days.</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">References</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Torres R, Czeisler EL, Chadwick SR, et al. Efficacy and safety of iloperidone in bipolar mania&#58; a double-blind, placebo-controlled study. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">J Clin Psychiatry.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> https&#58;&#47;&#47;doi.org&#47;10.4088&#47;JCP.23m14966 </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Carlin, J. L., Polymeropoulos, C., Camilleri, M., Lembo, A., Fisher, M., Kupersmith, C., Madonick, D., Moszczynski, P., Smieszek, S., Xiao, C., Birznieks, G., &#38; Polymeropoulos, M. H. (2024). The efficacy of tradipitant in patients with diabetic and idiopathic gastroparesis in phase III randomized placebo-controlled clinical trial. Clinical Gastroenterology and Hepatology. https&#58;&#47;&#47;doi.org&#47;10.1016&#47;j.cgh.2024.01.005  </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Carlin, J. L., Lieberman, V. R., Dahal, A., Keefe, M. S., Xiao, C., Birznieks, G., Abell, T. L., Lembo, A., Parkman, H. P., &#38; Polymeropoulos, M. H. (2021). Efficacy and Safety of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial. Gastroenterology, 160(1), 76&#8211;87.e4. https&#58;&#47;&#47;doi.org&#47;10.1053&#47;j.gastro.2020.07.029</font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Vanda Pharmaceuticals Inc.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X &#64;vandapharma.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS</font></div><div style="margin-top:6pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various statements in this press release, including, but not limited to, statements regarding the a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dvancement of Vanda&#8217;s clinical development pipeline and strengthening of its commercial presence, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda&#8217;s plans for pursuit of FDA approval of HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatments of insomnia and jet lag disorder, Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of bipolar I in adults and tradipitant in the treatment of symptoms of gastroparesis and the treatment of motion sickness, Vanda&#8217;s expectations regarding the timing of the FDA&#8217;s decisions with respect to the sNDAs for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the NDA for tradipitant, the potential for PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to treat a diverse group of inflammatory&#47;autoimmune disorders, the USPTO&#8217;s plans to issue the new PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent, the anticipated life of the patent and Vanda&#8217;s intentions to list the patent in the Orange Book are &#8220;forward-looking statements&#8221; under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda&#8217;s forward-looking statements include, among others, Vanda&#8217;s ability to complete the clinical development of the products in its pipeline and obtain regulatory approval and market acceptance of these products, Vanda&#8217;s ability to obtain FDA approval of the sNDAs for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the NDA for tradipitant, the FDA&#8217;s ability to meet the PDUFA target action dates for the sNDAs for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the NDA for tradipitant, the FDA&#8217;s assessment of the sufficiency of the data packages included in Vanda&#8217;s regulatory submissions for HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and tradipitant, Vanda&#8217;s ability to complete the clinical program for tradipitant in the treatment of motion sickness, the results of any clinical trials conducted for PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the treatment of other inflammatory&#47;autoimmune disorders and Vanda&#8217;s ability to obtain regulatory approval of PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for any such additional indications, the payment by Vanda to the USPTO of all fees required prior to the issuance of the new PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent, the ultimate issuance of the patent by the USPTO and Vanda&#8217;s ability to protect its intellectual property rights and defend the new PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent against any attempt to invalidate it. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda&#8217;s business and market, particularly those identified in the &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;, &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of Vanda&#8217;s most recent Annual Report on Form 10-K, as updated by Vanda&#8217;s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><div id="i2067d6f0c0ae44069ff03d1c80555484_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except for share and per share amounts)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31<br>2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31<br>2023</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31<br>2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HETLIOZ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,072&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,101&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,167&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,655&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fanapt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,599&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,381&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,873&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,727&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PONVORY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> net product sales</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,600&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,271&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,482&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,640&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,382&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold excluding amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,460&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,238&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,796&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,282&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,339&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,454&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,823&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,770&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,613&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,782&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,883&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,485&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,090&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,516&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,365&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,853&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,592&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,053&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,094)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,629&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,952)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,329&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,433&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,291&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,971&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,661)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,613&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,339&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,300&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,752&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,025&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,400)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,861&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,275&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, basic</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share, diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,532,309&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,651,984&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,380,975&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,461,877&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding, diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,532,309&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,188,551&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,557,911&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,983,171&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><div id="i2067d6f0c0ae44069ff03d1c80555484_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VANDA PHARMACEUTICALS INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31<br>2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,821&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,029&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,443&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,830&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,155&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,512&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,170&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,727&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,946&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519,292&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,037&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,573&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,103&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,369&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,565&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,039&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventory and other</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,985&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,378&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,440&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634,247&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,460&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,551&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue allowances</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,237&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,885&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,697&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,436&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,006&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,813&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,827&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,800&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,530&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,049&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,235&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,193)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,392)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(157,901)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544,910&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527,198&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,440&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634,247&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Contact&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevin Moran</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Chief Financial Officer and Treasurer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vanda Pharmaceuticals Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">202-734-3400</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pr&#64;vandapharma.com</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOURCE Vanda Pharmaceuticals Inc.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:right"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>vnda-20240207.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0fd38aba-6e9b-406c-afa4-6cc51d523e4f,g:c6d953cc-2d55-4c64-b08a-d22de5923083-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vnda="http://www.vandapharmaceuticals.com/20240207" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vandapharmaceuticals.com/20240207">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20240207_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20240207_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.vandapharmaceuticals.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>vnda-20240207_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0fd38aba-6e9b-406c-afa4-6cc51d523e4f,g:c6d953cc-2d55-4c64-b08a-d22de5923083-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_4eb52dd4-c951-4002-9386-bcdf2686679e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_34aee192-c8a6-4c2c-8325-30536cd72981_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_53a80d6c-aeeb-4194-be41-543a1f05ba64_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b8403dd8-9eef-4a06-8c6e-ff536d99be47_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b5d767a7-856a-49c5-9f87-2b77e2844e3c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_faa317f8-f41a-42bd-8946-e18765d4992e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_8932b89f-bdc8-4dd2-8548-35aa4a433f9c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_113c9253-c06a-4178-b6a1-0346e2e2ebe8_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_09e41059-aec0-4f79-b859-97f8a62df5ec_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ed08b4d7-4274-47e2-8ec9-f226941ad773_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9a763427-ac6e-4e6d-9a9a-3f4ce41d7953_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0142242f-d2d6-4b80-b0aa-f095a4cacef8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_8bc96772-e34e-40a6-9381-5c7ee7a0ad59_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b95421ff-1176-49e7-8fec-6368c898e26e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_39f94d22-0c2f-4357-9389-8b7f31983f6c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_959b8734-53f2-4973-b561-d71b330715cb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c573ae54-e4ce-40b7-83cb-311e9345aecc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_129d8abf-2e3e-4e53-a9ee-a2914692f4f6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8aca1b53-0c87-4a9a-925c-f0dad6cc0e71_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_06bba752-ef5d-42e6-967d-7559687a0b01_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0d76cf5a-e9c8-4c76-8f4d-96a82edc6a4d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_90524db0-3b08-48d2-9d93-55040d72a6fd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_f8f1d86d-c7bd-4e69-8917-2247be2abc79_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>vnda-20240207_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0fd38aba-6e9b-406c-afa4-6cc51d523e4f,g:c6d953cc-2d55-4c64-b08a-d22de5923083-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="simple" xlink:href="vnda-20240207.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a526316c-5f14-4b36-970e-9a388535d7a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_DocumentType_a526316c-5f14-4b36-970e-9a388535d7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ecaa6ea1-b99a-4b0d-b415-75090dca9fa9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_EntityRegistrantName_ecaa6ea1-b99a-4b0d-b415-75090dca9fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bcb36cc3-ffb4-428b-9b90-6b8799c686ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bcb36cc3-ffb4-428b-9b90-6b8799c686ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_960ad9f6-a0e2-451f-b9eb-dd5f57e43ee7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_EntityFileNumber_960ad9f6-a0e2-451f-b9eb-dd5f57e43ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_064bab9e-a246-473e-b884-a59ba6d4cd6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_EntityTaxIdentificationNumber_064bab9e-a246-473e-b884-a59ba6d4cd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6eca6f0e-380a-49c7-a0b9-78a514c7c9f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_EntityAddressAddressLine1_6eca6f0e-380a-49c7-a0b9-78a514c7c9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_3441e2b3-f370-4380-9d6b-73bcacdb1fb7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_EntityAddressAddressLine2_3441e2b3-f370-4380-9d6b-73bcacdb1fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_64532cf4-910e-418d-b5fc-0d384c716ca1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_EntityAddressCityOrTown_64532cf4-910e-418d-b5fc-0d384c716ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7ff3e4df-9982-4b0c-b845-7ec87df27682" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_EntityAddressStateOrProvince_7ff3e4df-9982-4b0c-b845-7ec87df27682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_648db071-fa2e-4a13-9441-ea234b3c5855" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_EntityAddressPostalZipCode_648db071-fa2e-4a13-9441-ea234b3c5855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d7f0a0fe-6406-48e6-8dd2-d92bd325919d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_CityAreaCode_d7f0a0fe-6406-48e6-8dd2-d92bd325919d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_956681d3-d60f-4ea0-8fe4-95135bf8e734" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_LocalPhoneNumber_956681d3-d60f-4ea0-8fe4-95135bf8e734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_218b21f9-8528-488c-bdf7-8588f0a7b848" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_WrittenCommunications_218b21f9-8528-488c-bdf7-8588f0a7b848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_4acd5b7b-1411-4641-a908-296fd0eb75f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_SolicitingMaterial_4acd5b7b-1411-4641-a908-296fd0eb75f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_684c2032-f503-4b94-a39e-b11b9cc6f69f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_PreCommencementTenderOffer_684c2032-f503-4b94-a39e-b11b9cc6f69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e2cd891f-170b-46cc-8db2-00cd3a3cbe8e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e2cd891f-170b-46cc-8db2-00cd3a3cbe8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_12139dec-12a0-401f-8127-a63053f8a51d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_Security12bTitle_12139dec-12a0-401f-8127-a63053f8a51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e2e3d559-7e01-4a19-bddd-a6a212f60fc0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_TradingSymbol_e2e3d559-7e01-4a19-bddd-a6a212f60fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_516638ec-34cf-47bd-8f3c-83f0cac802fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_SecurityExchangeName_516638ec-34cf-47bd-8f3c-83f0cac802fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dc57ed0f-9eef-4f9e-91f8-7b343e5c63c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_EntityEmergingGrowthCompany_dc57ed0f-9eef-4f9e-91f8-7b343e5c63c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4b7bfd5d-045a-4272-aa1e-7cb84454ba06" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_EntityCentralIndexKey_4b7bfd5d-045a-4272-aa1e-7cb84454ba06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f5cf3ed3-92db-4069-b793-a47f2405b932" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_AmendmentFlag_f5cf3ed3-92db-4069-b793-a47f2405b932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6ccf02b9-a6c5-4b5c-9e0e-30db9a727d16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_95b0d4b0-2f31-417f-a5ea-2ff65297b1fb" xlink:to="loc_dei_DocumentPeriodEndDate_6ccf02b9-a6c5-4b5c-9e0e-30db9a727d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>vandaq32019earningsca_imag.jpg
<TEXT>
begin 644 vandaq32019earningsca_imag.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M^RO?-WL^7]FN]]W Z;&SMY)I#YZ8T+D"O$D"@'F:#IFYGCM;=[F7^SC0L?L
MKUJY[NW-D]Z;IW%N[,R>7*[FS>3SN08$E!592LFK)8X@WZ((6ET1J.%10
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MCNH:K9M5U#L[?$LN^-G9O/9K^-9[-[NQ]<JUV/W=@X!1"#!P^./PEE8L2QN
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M6FE2 :T!-:5(%<<*CSZJG[DG_E&]*YRNZ_[0^1/777^^<94+C\OA!W&,EN_
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M[^MG,O[GV]Z[%MS,BT.))N$LGH0M/#C.<!F4TDZV6/Y%W\OA/AG\7:3L3?\
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MH>NC=K=6]]:QWMFZR6DR*Z.IJK(P#*P/F""".E![9Z?ZT%/^%+7_ &\4PO\
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M9]BN7"U[8KZ-HB1Z)<Q*T4I/E^G&OJW4BV.U;'S%$;GE'<[6]C J4UC6H_I
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MTY*13T'!@/TW/^F4:"3@:4'%NLP?NV\Z>-:S\CWS_J0UGMJGBC']:,?Z5B)
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M6+41%_LIE$J^T_)G]:-_%W>I79K(AY*C#O\ Z''\P2-3C^%=)IJ'4*^]W/\
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M@:>?_"EK_MXIA?\ Q7#K3_WJ>Q_>2OL7_P J4_\ SW2_\<BZQ$^\A_T\)/\
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M-)B\I4.?1!C**KD/"^YD]D^8(-HYH;;KI@L%_&(U)P/%4ZHP3_2!=!ZLRCJ
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M%\].'8?Q:/-3U)'W=.0/IX&Y\W-/UI0T=H",A/ADF%>!?,:'CI$G%7!Z2O\
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MC);34Z02305-!0$GCT8OV2="'KWOW7NO>_=>Z++\JOA]\>_FCUQ+UA\ANO\
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MZ57B: DGT  !))(  ))IUK==VV[8["3=-VF2"PB +.W 5( &*DDD@  $DD
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M,Y\(_P#LHS^9Y_XM_M3_ .!>Z']D/-7_ "1-A_Z5K_\ :5<=";DO_E8>9O\
MI;I_VA6O2*_EXTL,7PV[Z6EIHHWJ?DG\^&D6GA5&GF7Y ]L4L3.(U!ED6G@C
MC4FY"(JC@ >U7.C$\S6>HX%CM_\ VCPG_9Z1>WR <GWX4"IW+=.'G_C4X_P
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M_P !SVW[0<N_\JGS#_SS6G_:;#T9<U?\KORM_P ]=[_W;Y^O?S9O^R&M^?\
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(7NO>_=>Z_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140113222732288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Feb. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VANDA PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">03-0491827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2200 Pennsylvania Avenue NW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300E<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Washington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">734-3400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VNDA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001347178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  07,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " #C@$=8EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( ..
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MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( ..
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .. 1UA#''NL<@0  #01   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #C@$=8GZ ;\+$"  #B#   #0              @ &U#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( .. 1UB7BKL<P    !,"   +
M  "  9$/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .. 1U@9117U-P$  "<"
M   /              "  7H0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #C@$=8)!Z;HJT   #X 0  &@              @ '>$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #C@$=899!YDAD!  #/ P
M$P              @ '#$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"   -%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="vnda-20240207.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="vnda-20240207.htm">vnda-20240207.htm</File>
    <File>vnda-20240207.xsd</File>
    <File>vnda-20240207_lab.xml</File>
    <File>vnda-20240207_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vnda-20240207.htm": {
   "nsprefix": "vnda",
   "nsuri": "http://www.vandapharmaceuticals.com/20240207",
   "dts": {
    "inline": {
     "local": [
      "vnda-20240207.htm"
     ]
    },
    "schema": {
     "local": [
      "vnda-20240207.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "vnda-20240207_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vnda-20240207_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "report": {
    "R1": {
     "role": "http://www.vandapharmaceuticals.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vnda-20240207.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vnda-20240207.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-24-003693-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-003693-xbrl.zip
M4$L#!!0    ( .. 1UC"'[QWH10  -Z*   1    =FYD82TR,#(T,#(P-RYH
M=&WM/6M3XSBVW^=7J#+W;M-5Q+&=0![0;+%I>I::;IHE]/36_7)+L16BP;$\
MEIR0_?5[CB0G<1Z0T#P"35=UD=AZG?=#1\KAWV\&$1FR5'(1?WCG.>X[PN)
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M/X\OOARW3[Y=GK://W?(Z5G;6>6^;(4_MYZAVSFYH:"Y$!E&X',D$"J)3%B
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M?>K(=V8<MZGVE.NDV[?QP*BE0!G1W?)]9R^G H\QRFJ5F\^6\-T)WV^X(?^
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M$/$"#YP</'[1_FG_F>+DX+]02P,$%     @ XX!'6*IKL&T1*P  70T" !L
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MZEB(ZF @!C+M,)(H-[>QCRK>1'E(=(!(!;-EJB=F#R0(UD?31F">9ZH/?1"
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M)]L\@=L2+U\&8,:Z+;860&IW_(&DX(0__!I+FR+\Q>80O\H'@9T0$OY./;5
M0H!4(>?Q1!RI]@]E^>Y+4]/F:?"7GEL!Y"%/_'1?X"0%K=SREZ>'Y"L@DW2_
MLNORAO=>FVB\L:L<$*0-/X":J<R&?L8P!RG#G.X@\X1]+LP"R:YMF_.?@MX,
MI@#._12,@6(S? 60(?":T!H*.U;5X=9D"8!)JLE'Y-E\K+&_A.V*D#ZF_7$
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M)N=;W US:C>V%(O8AFMB_@9T;V_SLG$-Q]E291%+X,WZGKF-3/+@G5*G<1
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8=&U02P4&      4 !0!- 0  JE0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>vnda-20240207_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vnda-20240207.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2024-02-07</startDate>
            <endDate>2024-02-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001347178</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-02-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">VANDA PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-34186</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">03-0491827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2200 Pennsylvania Avenue NW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 300E</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Washington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">DC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">20037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">202</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">734-3400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">VNDA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
